Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs


Keane F. M. , Yao T., Seelk S., Gall M. G. , Chowdhury S., Poplawski S. E. , ...Daha Fazla

FEBS OPEN BIO, cilt.4, ss.43-54, 2014 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 4
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1016/j.fob.2013.12.001
  • Dergi Adı: FEBS OPEN BIO
  • Sayfa Sayıları: ss.43-54

Özet

The protease fibroblast activation protein (FAP) is a specific marker of activated mesenchymal cells in tumour stroma and fibrotic liver. A specific, reliable FAP enzyme assay has been lacking. FAP's unique and restricted cleavage of the post proline bond was exploited to generate a new specific substrate to quantify FAP enzyme activity. This sensitive assay detected no FAP activity in any tissue or fluid of FAP gene knockout mice, thus confirming assay specificity. Circulating FAP activity was similar to 20- and 1.3-fold less in baboon than in mouse and human plasma, respectively. Serum and plasma contained comparable FAP activity. In mice, the highest levels of FAP activity were in uterus, pancreas, submaxillary gland and skin, whereas the lowest levels were in brain, prostate, leukocytes and testis. Baboon organs high in FAP activity included skin, epididymis, bladder, colon, adipose tissue, nerve and tongue. FAP activity was greatly elevated in tumours and associated lymph nodes and in fungal-infected skin of unhealthy baboons. FAP activity was 14- to 18-fold greater in cirrhotic than in non-diseased human liver, and circulating FAP activity was almost doubled in alcoholic cirrhosis. Parallel DPP4 measurements concorded with the literature, except for the novel finding of high DPP4 activity in bile. The new FAP enzyme assay is the first to be thoroughly characterised and shows that FAP activity is measurable in most organs and at high levels in some. This new assay is a robust tool for specific quantitation of FAP enzyme activity in both preclinical and clinical samples, particularly liver fibrosis. (C) 2014 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies. All rights reserved.